Global Radioligand Therapy Market Research Report 2022
SKU ID : QYR-20704046 | Publishing Date : 12-Apr-2022 | No. of pages : 85
Detailed TOC of Global Radioligand Therapy Market Research Report 2022
1 Report Overview1.1 Study Scope
1.2 Market Analysis by Used Radionuclides
1.2.1 Global Radioligand Therapy Market Size Growth Rate by Used Radionuclides: 2017 VS 2021 VS 2028
1.2.2 Actinium 225 (Ac-225)
1.2.3 Lutetium 177 (Lu-177)
1.2.4 Gallium 68 (Ga-68)
1.2.5 Fluorine 18 (F-18)
1.2.6 Other Radionuclides
1.3 Market by Application
1.3.1 Global Radioligand Therapy Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Neuroendocrine Neoplasms
1.3.3 Prostate Cancer
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Radioligand Therapy Market Perspective (2017-2028)
2.2 Radioligand Therapy Growth Trends by Region
2.2.1 Radioligand Therapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Radioligand Therapy Historic Market Size by Region (2017-2022)
2.2.3 Radioligand Therapy Forecasted Market Size by Region (2023-2028)
2.3 Radioligand Therapy Market Dynamics
2.3.1 Radioligand Therapy Industry Trends
2.3.2 Radioligand Therapy Market Drivers
2.3.3 Radioligand Therapy Market Challenges
2.3.4 Radioligand Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radioligand Therapy Players by Revenue
3.1.1 Global Top Radioligand Therapy Players by Revenue (2017-2022)
3.1.2 Global Radioligand Therapy Revenue Market Share by Players (2017-2022)
3.2 Global Radioligand Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Radioligand Therapy Revenue
3.4 Global Radioligand Therapy Market Concentration Ratio
3.4.1 Global Radioligand Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radioligand Therapy Revenue in 2021
3.5 Radioligand Therapy Key Players Head office and Area Served
3.6 Key Players Radioligand Therapy Product Solution and Service
3.7 Date of Enter into Radioligand Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Radioligand Therapy Breakdown Data by Used Radionuclides
4.1 Global Radioligand Therapy Historic Market Size by Used Radionuclides (2017-2022)
4.2 Global Radioligand Therapy Forecasted Market Size by Used Radionuclides (2023-2028)
5 Radioligand Therapy Breakdown Data by Application
5.1 Global Radioligand Therapy Historic Market Size by Application (2017-2022)
5.2 Global Radioligand Therapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Radioligand Therapy Market Size (2017-2028)
6.2 North America Radioligand Therapy Market Size by Country (2017-2022)
6.3 North America Radioligand Therapy Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Radioligand Therapy Market Size (2017-2028)
7.2 Europe Radioligand Therapy Market Size by Country (2017-2022)
7.3 Europe Radioligand Therapy Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radioligand Therapy Market Size (2017-2028)
8.2 Asia-Pacific Radioligand Therapy Market Size by Country (2017-2022)
8.3 Asia-Pacific Radioligand Therapy Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Radioligand Therapy Market Size (2017-2028)
9.2 Latin America Radioligand Therapy Market Size by Country (2017-2022)
9.3 Latin America Radioligand Therapy Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radioligand Therapy Market Size (2017-2028)
10.2 Middle East & Africa Radioligand Therapy Market Size by Country (2017-2022)
10.3 Middle East & Africa Radioligand Therapy Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Radioligand Therapy Introduction
11.1.4 Novartis Revenue in Radioligand Therapy Business (2017-2022)
11.1.5 Novartis Recent Development
11.2 Advanced Accelerator Applications
11.2.1 Advanced Accelerator Applications Company Detail
11.2.2 Advanced Accelerator Applications Business Overview
11.2.3 Advanced Accelerator Applications Radioligand Therapy Introduction
11.2.4 Advanced Accelerator Applications Revenue in Radioligand Therapy Business (2017-2022)
11.2.5 Advanced Accelerator Applications Recent Development
11.3 Mercy Radiology
11.3.1 Mercy Radiology Company Detail
11.3.2 Mercy Radiology Business Overview
11.3.3 Mercy Radiology Radioligand Therapy Introduction
11.3.4 Mercy Radiology Revenue in Radioligand Therapy Business (2017-2022)
11.3.5 Mercy Radiology Recent Development
11.4 POINT Biopharma Global Inc
11.4.1 POINT Biopharma Global Inc Company Detail
11.4.2 POINT Biopharma Global Inc Business Overview
11.4.3 POINT Biopharma Global Inc Radioligand Therapy Introduction
11.4.4 POINT Biopharma Global Inc Revenue in Radioligand Therapy Business (2017-2022)
11.4.5 POINT Biopharma Global Inc Recent Development
11.5 Fusion Pharma
11.5.1 Fusion Pharma Company Detail
11.5.2 Fusion Pharma Business Overview
11.5.3 Fusion Pharma Radioligand Therapy Introduction
11.5.4 Fusion Pharma Revenue in Radioligand Therapy Business (2017-2022)
11.5.5 Fusion Pharma Recent Development
11.6 Telix Pharmaceuticals Ltd
11.6.1 Telix Pharmaceuticals Ltd Company Detail
11.6.2 Telix Pharmaceuticals Ltd Business Overview
11.6.3 Telix Pharmaceuticals Ltd Radioligand Therapy Introduction
11.6.4 Telix Pharmaceuticals Ltd Revenue in Radioligand Therapy Business (2017-2022)
11.6.5 Telix Pharmaceuticals Ltd Recent Development
11.7 Lantheus Holdings, Inc
11.7.1 Lantheus Holdings, Inc Company Detail
11.7.2 Lantheus Holdings, Inc Business Overview
11.7.3 Lantheus Holdings, Inc Radioligand Therapy Introduction
11.7.4 Lantheus Holdings, Inc Revenue in Radioligand Therapy Business (2017-2022)
11.7.5 Lantheus Holdings, Inc Recent Development
11.8 Bayer AG
11.8.1 Bayer AG Company Detail
11.8.2 Bayer AG Business Overview
11.8.3 Bayer AG Radioligand Therapy Introduction
11.8.4 Bayer AG Revenue in Radioligand Therapy Business (2017-2022)
11.8.5 Bayer AG Recent Development
11.9 Curium Pharma
11.9.1 Curium Pharma Company Detail
11.9.2 Curium Pharma Business Overview
11.9.3 Curium Pharma Radioligand Therapy Introduction
11.9.4 Curium Pharma Revenue in Radioligand Therapy Business (2017-2022)
11.9.5 Curium Pharma Recent Development
11.10 Precirix
11.10.1 Precirix Company Detail
11.10.2 Precirix Business Overview
11.10.3 Precirix Radioligand Therapy Introduction
11.10.4 Precirix Revenue in Radioligand Therapy Business (2017-2022)
11.10.5 Precirix Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Figures, Tables and Charts Available in Global Radioligand Therapy Market Research Report 2022
List of TablesTable 1. Global Radioligand Therapy Market Size Growth Rate by Used Radionuclides (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Actinium 225 (Ac-225)
Table 3. Key Players of Lutetium 177 (Lu-177)
Table 4. Key Players of Gallium 68 (Ga-68)
Table 5. Key Players of Fluorine 18 (F-18)
Table 6. Key Players of Other Radionuclides
Table 7. Global Radioligand Therapy Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Radioligand Therapy Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Radioligand Therapy Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Radioligand Therapy Market Share by Region (2017-2022)
Table 11. Global Radioligand Therapy Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Radioligand Therapy Market Share by Region (2023-2028)
Table 13. Radioligand Therapy Market Trends
Table 14. Radioligand Therapy Market Drivers
Table 15. Radioligand Therapy Market Challenges
Table 16. Radioligand Therapy Market Restraints
Table 17. Global Radioligand Therapy Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Radioligand Therapy Market Share by Players (2017-2022)
Table 19. Global Top Radioligand Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioligand Therapy as of 2021)
Table 20. Ranking of Global Top Radioligand Therapy Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Radioligand Therapy Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Radioligand Therapy Product Solution and Service
Table 24. Date of Enter into Radioligand Therapy Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Radioligand Therapy Market Size by Used Radionuclides (2017-2022) & (US$ Million)
Table 27. Global Radioligand Therapy Revenue Market Share by Used Radionuclides (2017-2022)
Table 28. Global Radioligand Therapy Forecasted Market Size by Used Radionuclides (2023-2028) & (US$ Million)
Table 29. Global Radioligand Therapy Revenue Market Share by Used Radionuclides (2023-2028)
Table 30. Global Radioligand Therapy Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Radioligand Therapy Revenue Market Share by Application (2017-2022)
Table 32. Global Radioligand Therapy Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Radioligand Therapy Revenue Market Share by Application (2023-2028)
Table 34. North America Radioligand Therapy Market Size by Country (2017-2022) & (US$ Million)
Table 35. North America Radioligand Therapy Market Size by Country (2023-2028) & (US$ Million)
Table 36. Europe Radioligand Therapy Market Size by Country (2017-2022) & (US$ Million)
Table 37. Europe Radioligand Therapy Market Size by Country (2023-2028) & (US$ Million)
Table 38. Asia-Pacific Radioligand Therapy Market Size by Region (2017-2022) & (US$ Million)
Table 39. Asia-Pacific Radioligand Therapy Market Size by Region (2023-2028) & (US$ Million)
Table 40. Latin America Radioligand Therapy Market Size by Country (2017-2022) & (US$ Million)
Table 41. Latin America Radioligand Therapy Market Size by Country (2023-2028) & (US$ Million)
Table 42. Middle East & Africa Radioligand Therapy Market Size by Country (2017-2022) & (US$ Million)
Table 43. Middle East & Africa Radioligand Therapy Market Size by Country (2023-2028) & (US$ Million)
Table 44. Novartis Company Detail
Table 45. Novartis Business Overview
Table 46. Novartis Radioligand Therapy Product
Table 47. Novartis Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 48. Novartis Recent Development
Table 49. Advanced Accelerator Applications Company Detail
Table 50. Advanced Accelerator Applications Business Overview
Table 51. Advanced Accelerator Applications Radioligand Therapy Product
Table 52. Advanced Accelerator Applications Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 53. Advanced Accelerator Applications Recent Development
Table 54. Mercy Radiology Company Detail
Table 55. Mercy Radiology Business Overview
Table 56. Mercy Radiology Radioligand Therapy Product
Table 57. Mercy Radiology Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 58. Mercy Radiology Recent Development
Table 59. POINT Biopharma Global Inc Company Detail
Table 60. POINT Biopharma Global Inc Business Overview
Table 61. POINT Biopharma Global Inc Radioligand Therapy Product
Table 62. POINT Biopharma Global Inc Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 63. POINT Biopharma Global Inc Recent Development
Table 64. Fusion Pharma Company Detail
Table 65. Fusion Pharma Business Overview
Table 66. Fusion Pharma Radioligand Therapy Product
Table 67. Fusion Pharma Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 68. Fusion Pharma Recent Development
Table 69. Telix Pharmaceuticals Ltd Company Detail
Table 70. Telix Pharmaceuticals Ltd Business Overview
Table 71. Telix Pharmaceuticals Ltd Radioligand Therapy Product
Table 72. Telix Pharmaceuticals Ltd Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 73. Telix Pharmaceuticals Ltd Recent Development
Table 74. Lantheus Holdings, Inc Company Detail
Table 75. Lantheus Holdings, Inc Business Overview
Table 76. Lantheus Holdings, Inc Radioligand Therapy Product
Table 77. Lantheus Holdings, Inc Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 78. Lantheus Holdings, Inc Recent Development
Table 79. Bayer AG Company Detail
Table 80. Bayer AG Business Overview
Table 81. Bayer AG Radioligand Therapy Product
Table 82. Bayer AG Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 83. Bayer AG Recent Development
Table 84. Curium Pharma Company Detail
Table 85. Curium Pharma Business Overview
Table 86. Curium Pharma Radioligand Therapy Product
Table 87. Curium Pharma Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 88. Curium Pharma Recent Development
Table 89. Precirix Company Detail
Table 90. Precirix Business Overview
Table 91. Precirix Radioligand Therapy Product
Table 92. Precirix Revenue in Radioligand Therapy Business (2017-2022) & (US$ Million)
Table 93. Precirix Recent Development
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Radioligand Therapy Market Share by Used Radionuclides: 2021 VS 2028
Figure 2. Actinium 225 (Ac-225) Features
Figure 3. Lutetium 177 (Lu-177) Features
Figure 4. Gallium 68 (Ga-68) Features
Figure 5. Fluorine 18 (F-18) Features
Figure 6. Other Radionuclides Features
Figure 7. Global Radioligand Therapy Market Share by Application in 2021 & 2028
Figure 8. Neuroendocrine Neoplasms Case Studies
Figure 9. Prostate Cancer Case Studies
Figure 10. Radioligand Therapy Report Years Considered
Figure 11. Global Radioligand Therapy Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 12. Global Radioligand Therapy Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Radioligand Therapy Market Share by Region: 2021 VS 2028
Figure 14. Global Radioligand Therapy Market Share by Players in 2021
Figure 15. Global Top Radioligand Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioligand Therapy as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Radioligand Therapy Revenue in 2021
Figure 17. North America Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 18. North America Radioligand Therapy Market Share by Country (2017-2028)
Figure 19. United States Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Canada Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Radioligand Therapy Market Share by Country (2017-2028)
Figure 23. Germany Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. France Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. U.K. Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Italy Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Russia Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Nordic Countries Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Asia-Pacific Radioligand Therapy Market Share by Region (2017-2028)
Figure 31. China Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Japan Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. South Korea Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Southeast Asia Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. India Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Australia Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Latin America Radioligand Therapy Market Share by Country (2017-2028)
Figure 39. Mexico Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Brazil Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Middle East & Africa Radioligand Therapy Market Share by Country (2017-2028)
Figure 43. Turkey Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Saudi Arabia Radioligand Therapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Novartis Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 46. Advanced Accelerator Applications Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 47. Mercy Radiology Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 48. POINT Biopharma Global Inc Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 49. Fusion Pharma Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 50. Telix Pharmaceuticals Ltd Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 51. Lantheus Holdings, Inc Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 52. Bayer AG Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 53. Curium Pharma Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 54. Precirix Revenue Growth Rate in Radioligand Therapy Business (2017-2022)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Keyplayers in Global Radioligand Therapy Market Research Report 2022
NovartisAdvanced Accelerator Applications
Mercy Radiology
POINT Biopharma Global Inc
Fusion Pharma
Telix Pharmaceuticals Ltd
Lantheus Holdings, Inc
Bayer AG
Curium Pharma
Precirix